FDA Approves Kebilidi Gene Therapy for AADC Deficiency and Accepts BLA for Pz-cel in RDEB
核心洞察
The FDA has approved Kebilidi, the first gene therapy for aromatic L-amino acid decarboxylase (AADC) deficiency, administered via infusions into the brain.
A Biologics License Application (BLA) resubmission for prademagene zamikeracel (pz-cel) to treat recessive dystrophic epidermolysis bullosa (搜索) (RDEB) has been accepted by the FDA, with a target action date of April 25, 2025.
Updated guidelines for resuscitation following drowning have been jointly released by the American Academy of Pediatrics (AAP) and the American Heart Association (AHA), based on systematic reviews.
The FDA has approved Kebilidi as the first gene therapy for treating aromatic L-amino acid decarboxylase (AADC) deficiency, a rare genetic disorder that can cause severe motor and developmental impairments. Additionally, the FDA has accepted the resubmitted Biologics License Application (BLA) for prademagene zamikeracel (pz-cel) for the treatment of recessive dystrophic epidermolysis bullosa (搜索) (RDEB), setting a target action date for approval in April 2025. These developments mark significant advancements in the treatment of rare and debilitating conditions.
Kebilidi Approved for AADC Deficiency
Kebilidi, a gene therapy administered through four infusions in a single surgical session directly into a key motor control structure in the brain, offers a new treatment option for patients with AADC deficiency. The therapy is intended to be administered in specialized medical centers equipped for pediatric stereotactic neurosurgery.
"AADC deficiency can cause a range of debilitating symptoms, including life-threatening complications," stated Nicole Verdun, MD, director of the Office of Therapeutic Products in CBER, in a press release. "Today’s approval represents important progress in the advancement and availability of safe and effective treatments for debilitating genetic disorders."
BLA Resubmission Accepted for Pz-cel in RDEB
Abeona Therapeutics announced that the FDA has accepted the resubmission of its BLA for prademagene zamikeracel (pz-cel) as a potential treatment for recessive dystrophic epidermolysis bullosa (搜索) (RDEB). The FDA has assigned a target action date of April 25, 2025.
Pz-cel, an investigational autologous, COL7A1 (搜索) gene-corrected epidermal sheet, had previously received Priority Review, but its approval was delayed following a Complete Response Letter (CRL) issued in April 2024.
Updated Resuscitation Guidelines Following Drowning
The American Academy of Pediatrics (AAP) and the American Heart Association (AHA) have jointly updated their guidelines for resuscitation following drowning. Published in Pediatrics and Circulation, the updated guidance is based on seven systematic reviews by the International Liaison Committee on Resuscitation task force.
The reviews covered critical topics, including:
- In-water resuscitation versus delayed resuscitation
- Oxygen administration following drowning
- AED first versus CPR first in cardiac arrest after drowning
- Chest compressions, airway, breathing versus airway, breathing, chest compressions
- Implementation of PAD programs
- Ventilation with equipment versus without equipment before hospital arrival following drowning
- Compression-only CPR
Identifying Drug-Resistant Epilepsy in Primary Care
Drug-resistant epilepsy (搜索) remains a significant challenge in pediatric care. H. Westley Phillips, MD, pediatric neurosurgeon-scientist and epilepsy researcher at Stanford Medicine Children’s Health, noted that “If a patient fails two medications, the likelihood that the next medication will result in seizure freedom is less than 5%.”
Phillips emphasized the importance of early detection and referral, stating, “We have very recent data demonstrating that the time from diagnosis of epilepsy (搜索) to surgical evaluation can be upwards of 16 years.” He encouraged pediatricians to maintain a high index of suspicion and promptly refer patients with suspected seizures to pediatric neurologists.